Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.0K
Overview
83.0K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

14.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minor histocompatibility antigen TCR-T.

Blood advances·2026
Same author

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Blood advances·2026
Same author

Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma.

Frontiers in oncology·2026
Same author

Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.

Nature communications·2026
Same author

The TCXpress lane to T-cell receptor-engineered T cells.

Blood advances·2026
Same author

The TCXpress lane to T-cell receptor-engineered T cells.

Blood advances·2026
Same journal

Pulmonary fibrosis after COVID-19 is characterized by airway abnormalities and elevated club cell secretory protein-16.

JCI insight·2026
Same journal

Fibroblasts: a diverse population of cells balancing homeostasis, wound healing, regeneration, inflammation, fibrosis, and cancer across organs.

JCI insight·2026
Same journal

Turning the tide on organ fibrosis: a special issue on scientific advances and next-generation treatments.

JCI insight·2026
Same journal

Microvascular autophagy and caspase-3 activation are central regulators of renal fibrosis after ischemia-reperfusion.

JCI insight·2026
Same journal

The extracellular matrix in cancer-associated fibrosis: molecular mechanisms and clinical relevance.

JCI insight·2026
Same journal

The inflammatory/fibrotic axis across organs: myelofibrosis as a model of reversibility.

JCI insight·2026
See all related articles

Related Experiment Video

Updated: Dec 22, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.8K

T cell optimization for graft-versus-leukemia responses.

Melinda A Biernacki1,2, Vipul S Sheth1, Marie Bleakley1,3

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

JCI Insight
|May 8, 2020
PubMed
Summary
This summary is machine-generated.

Graft-versus-leukemia (GVL) immune responses from donor T cells protect against relapse after hematopoietic cell transplantation (HCT). Enhancing GVL effects from alpha-beta and gamma-delta T cells may improve HCT outcomes.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.6K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.2K

Related Experiment Videos

Last Updated: Dec 22, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.8K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.6K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.2K

Area of Science:

  • Immunology
  • Transplantation Biology
  • Oncology

Background:

  • Allogeneic hematopoietic cell transplantation (HCT) relies on donor T cells for graft-versus-leukemia (GVL) responses to prevent relapse.
  • Relapse post-HCT remains a significant challenge, necessitating strategies to bolster anti-leukemia immunity.
  • Understanding T cell subsets and their specificities is crucial for optimizing GVL efficacy.

Purpose of the Study:

  • To explore the mechanisms of T cell-mediated GVL responses in HCT.
  • To identify strategies for enhancing GVL effects to improve outcomes for HCT recipients.
  • To investigate the roles of both alpha-beta (αβ) and gamma-delta (γδ) T cells in GVL.

Main Methods:

  • Review of existing literature on T cell receptor (TCR) recognition of antigens in HCT.
  • Analysis of the known specificities of αβ T cells, including minor histocompatibility antigens, alloantigens, leukemia-associated antigens, and neoantigens.
  • Discussion of the potential contributions and less understood biology of γδ T cells in GVL.

Main Results:

  • αβ T cells mediate GVL by recognizing minor histocompatibility antigens and alloantigens.
  • αβ T cells can also target leukemia via other antigens like neoantigens.
  • The role and specificity of γδ T cells in GVL are still under investigation but show potential contribution.

Conclusions:

  • Augmenting GVL responses is key to improving HCT outcomes.
  • Strategies like vaccination or adoptive T cell transfer could enhance specific αβ and γδ T cell GVL activities.
  • Targeting both known and novel T cell specificities holds promise for stronger anti-leukemia effects post-HCT.